Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple...Option Agreement • January 25th, 2021 • Acer Therapeutics Inc. • Pharmaceutical preparations
Under the terms of the Option Agreement, Acer will receive from Relief a $1 million non-refundable payment in return for exclusivity until June 30, 2021 to negotiate and enter into a definitive collaboration and license agreement between Acer and Relief for the development of ACER-001. Further, in connection with entering into the Option Agreement, Relief will make a $4.0 million loan to Acer. The loan, which will be secured by a lien on all of Acer's assets, will bear interest at the rate of 6% per annum and will be due in one year.
SECURITY AGREEMENTSecurity Agreement • January 25th, 2021 • Acer Therapeutics Inc. • Pharmaceutical preparations • New York
This SECURITY AGREEMENT ("Agreement") is made as of this 25th day of January, 2021, by Acer Therapeutics Inc., a Delaware corporation (the "Grantor") in favor of Relief Therapeutics Holding AG, a corporation organized under the laws of Switzerland (the "Secured Party").
OPTION AGREEMENTOption Agreement • January 25th, 2021 • Acer Therapeutics Inc. • Pharmaceutical preparations • New York
This Option Agreement (“Agreement”) is made and entered into as of January 25, 2021 (the “Effective Date”), by and between Acer Therapeutics Inc., a company organized and existing under the laws of Delaware (“Acer”), and Relief Therapeutics Holding AG, a company organized and existing under the laws of Switzerland (“Relief”). Relief and Acer each may be referred to herein individually as a “Party” or collectively as the “Parties.”
